Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) has received a consensus recommendation of “Buy” from the ...
Late on Thursday night and into the early hours of Friday, the full moon turned a beautiful reddish color as it drifted ...
An automated 3D vision-guided robotic system has been developed by Goldfuß Engineering and SIMON IBV to accelerate the ...
Early crew members of the voyaging canoe Hokulea have gathered in Hawaii to celebrate the vessel's 50th birthday. The Hokulea ...
Arcturus Therapeutics (ARCT) had a challenging fourth quarter, with revenue and earnings falling short of analyst ...
Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $68 from $74 and keeps a Buy rating on the ...
Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research report issued on Friday,Benzinga reports. ARCT has been the ...
and SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European ...
This page features the latest Arcturus Therapeutics Holdings Inc share stories and breaking news. Assess the latest information about the Arcturus Therapeutics Holdings Inc stock. Our team of expert ...
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...
“KOSTAIVE and sa-mRNA technology signify a major advancement in vaccine innovation, providing the potential for broader and more enduring protection,” said Joseph Payne, CEO of Arcturus. “This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results